Merck & Co.’s stock was flat to lower on Tuesday after the company swung to a second-quarter loss as it booked a charge related to its $10.8 billion acquisition of Prometheus Biosciences Inc.
The company
MRK,
-0.90%
swung to a net loss of $4.975 billion, or $2.35 a share, for the quarter, after income of $3.944 billion, or $1.55 a share, in the year-earlier period. The number includes a $4.02-a-share charge from the Prometheus deal.
Excluding that charge, the company’s adjusted loss per share was $2.06, narrower than the loss of $2.18 forecast by FactSet analysts.
Sales rose 3% to $15.035 billion from $14.593 billion a year ago, also ahead of the $14.442 billion FactSet consensus.
Earnings were hit by a slump in sales of the company’s COVID antiviral Lagevrio, which fell 83% to $203 million, as the world has increasingly moved on from the pandemic. Lagevrio is an oral antiviral authorized for treatment of mild to moderate COVID.
Pfizer Inc.
PFE,
-1.28%
also got hit in the quarter by a slump in demand for its COVID products — its vaccine and its antiviral Paxlovid.
Sales of Merck’s Keytruda cancer treatment rose 19% to $6.3 billion, while sales of the human papillomavirus vaccine Gardasil rose 47% to $2.5 billion.
See also: Johnson & Johnson joins Merck, others in fighting Medicare drug-price program
Related: Merck lawsuit challenging Medicare drug-price negotiation signals long battle ahead, experts say
Overall, pharmaceutical sales rose 6% to $13.5 billion, while animal-health revenue fell 1% to $1.46 billion.
The company is expecting the acquisition of Prometheus to accelerate its presence in immunology and diversify its pipeline.
Prometheus is a clinical-stage biotechnology company focusing on autoimmune treatments, such as PRA023, a treatment under development for illnesses such as ulcerative colitis and Crohn’s disease.
Merck is now expecting full-year sales of $58.6 billion to $59.6 billion, while FactSet analysts expect $58.7 billion. Merck expects its full-year adjusted EPS to range from $2.95 to $3.05, compared with a FactSet consensus of $2.90.
The stock is down 3.9% in the year to date, while the S&P 500
SPX,
-0.19%
has gained 19.5%.
Also see: Moderna, Merck combo cancer-vaccine treatment shows ‘significant’ promise
Read the full article here